Welcome to our dedicated page for Abeona Therapeut SEC filings (Ticker: ABEO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Abeona Therapeutics Inc. (ABEO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, and its filings offer detailed insight into the business, including the commercialization of ZEVASKYN® (prademagene zamikeracel) for recessive dystrophic epidermolysis bullosa (RDEB) and the development of AAV-based gene therapies for ophthalmic conditions.
Investors can review current reports on Form 8-K, where Abeona reports material events such as quarterly financial results, operational updates on ZEVASKYN manufacturing and launch activities, and transactions like the sale of a Rare Pediatric Disease Priority Review Voucher awarded upon FDA approval of ZEVASKYN. These filings also confirm that Abeona’s common stock, with a par value of $0.01 per share, trades on The Nasdaq Capital Market under the symbol ABEO.
In addition to 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) for information on Abeona’s research and development spending, selling, general and administrative expenses related to the ZEVASKYN launch, cash and investment balances, debt obligations, and risk factor disclosures relevant to its gene therapy programs and manufacturing operations.
Stock Titan enhances these documents with AI-powered summaries that help explain key sections of lengthy filings, such as revenue descriptions, cost structures, and updates on regulatory interactions. The platform also surfaces insider transaction reports on Form 4 when filed, enabling users to track equity awards and other changes in beneficial ownership by Abeona’s officers and directors.
By combining real-time EDGAR updates with AI-generated highlights, this ABEO filings page is designed to make Abeona’s complex biopharmaceutical and gene therapy disclosures more accessible to investors, analysts, and other interested readers.
Abeona Therapeutics Inc. filed a report sharing a business update on the commercial launch of its FDA-approved gene therapy ZEVASKYN for recessive dystrophic epidermolysis bullosa (RDEB). Launch activities began in late 2025, with the first patient treated in December before a scheduled facility shutdown.
Manufacturing resumed in late January 2026, with multiple biopsies collected, one additional patient treatment completed, and further biopsies scheduled this quarter. Access is expanding, with coverage policies published by major commercial payers representing about 80 percent of commercially insured lives, full Medicaid coverage, and a permanent CMS HCPCS J-code J3389 effective January 1, 2026.
Abeona Therapeutics Inc. received an amended Schedule 13G/A from Adage Capital Management and related reporting persons indicating they no longer beneficially own any shares of Abeona common stock. As of December 31, 2025, each reporting person reports 0 shares and 0% ownership, with no voting or dispositive power.
The filing confirms that these institutional and individual holders now own 5 percent or less of Abeona’s common stock and that any securities previously acquired were held in the ordinary course of business, not for the purpose of influencing control of the company.
A shareholder of ABEO plans to sell 20,070 shares of common stock under Rule 144. The planned sale, through broker Stifel Nicolaus & Company Inc., has an aggregate market value of $102,168.00 and is listed for execution on or about 02/02/2026 on the Nasdaq.
The seller previously acquired 36,101 shares of common stock on 01/31/2026 via restricted stock units granted as equity compensation by the issuer and paid in equity rather than cash.
Abeona Therapeutics director Christine Berni Silverstein reported a tax-related stock sale. On February 2, 2026, she sold 20,070 shares of common stock at a weighted average price of $5.0906 per share. After this transaction, she beneficially owned 137,722 shares, held directly.
The filing notes the sale was made to cover tax obligations arising from the vesting of restricted stock awards, indicating the transaction was tied to equity compensation rather than a discretionary open-market liquidation. The price range for the sales was between $5.09 and $5.12 per share.
Abeona Therapeutics director Donald A. Wuchterl reported a small stock sale mainly for tax purposes. On 02/02/2026, he sold 14,814 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share to cover tax obligations from vesting restricted stock awards.
After this transaction, he directly owned 167,935 shares of Abeona common stock. The shares were sold in multiple trades within a narrow price range from $5.09 to $5.12 per share.
Abeona Therapeutics director Eric Crombez reported a sale of company stock. On 02/02/2026, he sold 16,284 shares of Abeona Therapeutics common stock at a weighted average price of $5.0906 per share in market transactions.
According to the disclosure, this sale was made to cover tax obligations arising from the vesting of restricted stock awards. After these transactions, Crombez beneficially owned 63,456 shares of Abeona Therapeutics common stock directly.
Abeona Therapeutics insider plans Rule 144 stock sale. A holder has filed to sell 14,814 shares of Abeona Therapeutics common stock, with an aggregate market value of $75,412.00, through Stifel Nicolaus on the Nasdaq exchange around 02/02/2026.
The shares relate to equity compensation: 36,101 common shares were acquired on 01/31/2026 via restricted stock units granted by the issuer and paid in equity. Common shares outstanding were 54,191,361 at the time of the notice.
A holder of ABEO common stock has filed a notice of proposed sale under Rule 144 to sell 16,284 shares through broker Stifel Nicolaus & Company Inc. on or about February 2, 2026 on the Nasdaq, with an aggregate market value of $82,886.00.
The filing notes that 36,101 common shares were acquired on January 31, 2026 as restricted stock units from the issuer as equity compensation. The issuer had 54,191,361 shares of this class outstanding at the time referenced.
Abeona Therapeutics insider Mark Alvino filed a notice of proposed sale of 2,000 shares of common stock. The shares are planned to be sold through Stifel Nicolaus & Company on Nasdaq around 02/02/2026, with an aggregate market value of $10,180.00.
The 2,000 shares were acquired on 01/31/2026 as restricted stock units granted by the issuer as equity compensation. Over the past three months, Alvino has already sold 15,000 and 13,500 common shares, generating gross proceeds of $71,168.00 and $70,574.00, respectively.
Abeona Therapeutics shareholder filed a notice of proposed sale under Rule 144 for 18,065 shares of common stock through Stifel Nicolaus & Company on 02/02/2026 on Nasdaq. The filing lists an aggregate market value of $91,962.00 for these shares and notes that 54,191,361 shares of common stock were outstanding.
The seller acquired 36,101 shares of common stock on 01/31/2026 via restricted stock units granted as equity compensation from the issuer, with payment also dated 01/31/2026. The form states the signer represents they are not aware of undisclosed material adverse information about Abeona’s current or prospective operations.